1. Human immune organoids to decode B cell response in healthy donors and patients with lymphoma
- Author
-
Zhong, Zhe, Quiñones-Pérez, Manuel, Dai, Zhonghao, Juarez, Valeria M., Bhatia, Eshant, Carlson, Christopher R., Shah, Shivem B., Patel, Anjali, Fang, Zhou, Hu, Thomas, Allam, Mayar, Hicks, Sakeenah L., Gupta, Mansi, Gupta, Sneh Lata, Weeks, Ethan, Vagelos, Stephanie D., Molina, Alejandro, Mulero-Russe, Adriana, Mora-Boza, Ana, Joshi, Devyani J., Sekaly, Rafick P., Sulchek, Todd, Goudy, Steven L., Wrammert, Jens, Roy, Krishnendu, Boss, Jeremy M., Coskun, Ahmet F., Scharer, Christopher D., García, Andrés J., Koff, Jean L., and Singh, Ankur
- Abstract
Antibodies are produced when naive B cells differentiate into plasma cells within germinal centres (GCs) of lymphoid tissues. Patients with B cell lymphoma on effective immunotherapies exhibit diminished antibody production, leading to higher infection rates and reduced vaccine efficacy, even after B cell recovery. Current ex vivo models fail to sustain long-term GC reactions and effectively test B cell responses. Here we developed synthetic hydrogels mimicking the lymphoid tissue microenvironment, enabling human GCs from tonsils and peripheral blood mononuclear cell-derived B cells. Immune organoids derived from peripheral blood mononuclear cells maintain GC B cells and plasma cells longer than tonsil-derived ones and exhibit unique B cell programming, including GC compartments, somatic hypermutation, immunoglobulin class switching and B cell clones. Chemical inhibition of transcriptional and epigenetic processes enhances plasma cell formation. While integrating polarized CXCL12 protein in a lymphoid organ-on-chip modulates GC responses in healthy donor B cells, it fails with B cells derived from patients with lymphoma. Our system allows rapid, controlled modelling of immune responses and B cell disorders.
- Published
- 2024
- Full Text
- View/download PDF